GlassScriptPhysician profile
David Jay Altszuler
NPI 1003177965
$3,890.62
in general payments reported to CMS, 2019-2025
32 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $223 · 2021: $549 · 2022: $528 · 2023: $913 · 2024: $812 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $617.74 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $567.95 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $327.85 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $294.20 | 2021-2025 | Nexletol |
| Cvrx, INC. | $233.82 | 2023 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $205.49 | 2019-2024 | Farxiga, Wainua |
| Amgen INC. | $184.09 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $121.06 | 2020-2023 | Cardiomems |
| Alnylam Pharmaceuticals INC. | $120.34 | 2019-2025 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $113.15 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.41 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $92.09 | 2022-2025 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $82.32 | 2022-2023 | Arcalyst |
| Scpharmaceuticals INC. | $79.98 | 2024-2025 | |
| Amarin Pharma, INC. | $76.74 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $72.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $68.10 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $64.80 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2020-2024 | |
| Actelion Pharmaceuticals US, INC. | $49.64 | 2024 | Opsumit, Uptravi |
| Genzyme Corporation | $46.72 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $45.87 | 2019 | |
| Boston Scientific Corporation | $41.72 | 2025 | Varithena Administration Pack |
| Daiichi Sankyo INC. | $41.15 | 2023 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.06 | 2019 | |
| Bracco Diagnostics INC. | $31.71 | 2025 | |
| Lantheus Medical Imaging, INC. | $27.75 | 2022 | |
| Impulse Dynamics (USA) INC. | $23.31 | 2022 | |
| Itamar Medical INC | $17.82 | 2021 | |
| Bardy Diagnostics, INC. | $16.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.33 | 2021 | |
| Medtronic, INC. | $13.52 | 2024 | Symplicity G3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Altszuler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.